Abstract
Marijuana use is disproportionately prevalent among HIV-infected individuals. The strongest neurocognitive effect of marijuana use is impairment in the domain of memory. Memory impairment is also high among HIV-infected persons. The present study examined 69 HIV-infected individuals who were stratified by age of regular marijuana initiation to investigate how marijuana use impacts neurocognitive functioning. A comprehensive battery assessed substance use and neurocognitive functioning. Findings indicated early onset marijuana users (regular use prior to age 18), compared to non-marijuana users and late onset marijuana users (regular use at age 18 or later), were over 8 times more likely to have learning impairment and nearly 4 times more likely to have memory impairment. A similar pattern of early onset marijuana users performing worse in learning emerged when examining domain deficit scores. The potential for early onset of regular marijuana use to exacerbate already high levels of memory impairment among HIV-infected persons has important clinical implications, including increased potential for medication non-adherence and difficulty with independent living.
Similar content being viewed by others
References
Mimiaga MJ, Reisner SL, Grasso C, et al. Substance use among HIV-infected patients engaged in primary care in the United States: findings from the Centers for AIDS Research Network of Integrated Clinical Systems cohort. Am J Public Health. 2013;103(8):1457–67.
Substance Abuse and Mental Health Services Administration. Behavioral health trends in the United States: results from the 2014 National Survey on Drug Use and Health. Rockville: SAMHSA; 2015.
Bruce D, Harper GW, Fernandez MI. Heavy marijuana use among gay and bisexual male emerging adults living with HIV/AIDS. J HIV AIDS Soc Serv. 2013;12(1):26–48.
Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manag. 2005;29(4):358–67.
National Organization for the Reform of Marijuana Laws. State laws: medicinal marijuana. 2017; http://norml.org/legal/medical-marijuana-2. Accessed 19 Jan 2017.
Valcour V, Sithinamsuwan P, Letendre S, Ances B. Pathogenesis of HIV in the central nervous system. Curr HIV/AIDS Rep. 2011;8(1):54–61.
Antinori A, Arendt G, Becker JT, et al. Updated research nosology for HIV-associated neurocognitive disorders. Neurology. 2007;69(18):1789–99.
Heaton RK, Clifford DB, Franklin DR Jr, et al. HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER Study. Neurology. 2010;75(23):2087–96.
Heaton RK, Franklin D, Ellis R, et al. HIV-associated neurocognitive disorders before and during the era of combination antiretroviral therapy: differences in rates, nature, and predictors. J Neurovirol. 2011;17(1):3–16.
Schiller A, Foley J, Burns W, Sellers AL, Golden C. Subcortical profile of memory compromise among HIV-1-infected individuals. Int J Neurosci. 2009;119(10):1779–803.
Scott J, Woods S, Carey C, Weber E, Bondi M, Grant I. Neurocognitive consequences of HIV infection in older adults: an evaluation of the “cortical” hypothesis. AIDS Behav. 2011;15(6):1187–96.
Maki PM, Cohen MH, Weber K, et al. Impairments in memory and hippocampal function in HIV-positive vs HIV-negative women: a preliminary study. Neurology. 2009;72(19):1661–8.
Moore D, Letendre S, Morris S, et al. Neurocognitive functioning in acute or early HIV infection. J Neurovirol. 2011;17(1):50–7.
Wright MJ, Woo E, Foley J, et al. Antiretroviral adherence and the nature of HIV-associated verbal memory impairment. Am Neuropsych Assoc. 2011;23(3):324–31.
Reger M, Welsh R, Razani J, Martin DJ, Boone KB. A meta-analysis of the neuropsychological sequelae of HIV infection. J Int Neuropsychol Soc. 2002;8(3):410–24.
Maki PM, Rubin LH, Valcour V, et al. Cognitive function in women with HIV: findings from the Women’s Interagency HIV Study. Neurology. 2015;84(3):231–40.
Martin EM, Nixon H, Pitrak DL, et al. Characteristics of prospective memory deficits in HIV-seropositive substance-dependent individuals: preliminary observations. J Clin Exp Neuropsychol. 2007;29(5):496–504.
Waldrop D, Ownby RL, Kumar M. Serial position effects in HIV-infected injecting drug users. Int J Neurosci. 2004;114(4):493–516.
Woods SP, Dawson MS, Weber E, Grant I. The semantic relatedness of cue–intention pairings influences event-based prospective memory failures in older adults with HIV infection. J Clin Exp Neuropsychol. 2010;32(4):398–407.
Ellis RJ, Badiee J, Vaida F, et al. Nadir CD4 is a predictor of HIV neurocognitive impairment in the era of combination antiretroviral therapy. AIDS. 2011;25(14):1747–51.
Valcour V, Yee P, Williams AE, et al. Lowest ever CD4 lymphocyte count (CD4 nadir) as a predictor of current cognitive and neurological status in human immunodeficiency virus type 1 infection–The Hawaii Aging with HIV Cohort. J Neurovirol. 2006;12(5):387–91.
D’Amico R, Yang Y, Mildvan D, et al. Lower CD4+ T lymphocyte nadirs may indicate limited immune reconstitution in HIV-1 infected individuals on potent antiretroviral therapy: analysis of immunophenotypic marker results of AACTG 5067. J Clin Immunol. 2005;25(2):106–15.
Gonzalez R. Acute and non-acute effects of cannabis on brain functioning and neuropsychological performance. Neuropsychol Rev. 2007;17(3):347–61.
Grant I, Gonzalez R, Carey C, Natara L, Woflson T. Non-acute (residual) neurocognitive effects of cannabis use: a meta-analytic study. J Int Neuropsychol Soc. 2003;9(5):679–89.
Crane NA, Schuster RM, Fusar-Poli P, Gonzalez R. Effects of cannabis on neurocognitive functioning: recent advances, neurodevelopmental influences, and sex differences. Neuropsychol Rev. 2013;23(2):117–37.
Schreiner AM, Dunn ME. Residual effects of cannabis use on neurocognitive performance after prolonged abstinence: a meta-analysis. Exp Clin Psychopharmacol. 2012;20(5):420–9.
Solowij N, Battisti R. The chronic effects of cannabis on memory in humans: a review. Curr Drug Abuse Rev. 2008;1(1):81–98.
Ranganathan M, D’Souza D. The acute effects of cannabinoids on memory in humans: a review. Psychopharmacology. 2006;188(4):425–44.
Volkow ND, Swanson JM, Evins A, et al. Effects of cannabis use on human behavior, including cognition, motivation, and psychosis: a review. JAMA Psychiatry. 2016;73(3):292–7.
Solowij N, Pesa N. Cannabis and cognition: short- and long-term effects. In: Castle D, Murray R, D’Souza D, editors. Marijuana and madness. 2nd ed. Cambridge: Cambridge University Press; 2012.
Meier MH, Caspi A, Ambler A, et al. Persistent cannabis users show neuropsychological decline from childhood to midlife. PNAS. 2012;109(40):E2657–64.
Pope HG Jr, Gruber AJ, Hudson JI, Cohane G, Huestis MA, Yurgelun-Todd D. Early-onset cannabis use and cognitive deficits: what is the nature of the association? Drug Alcohol Depend. 2003;69(3):303–10.
Gruber SA, Sagar KA, Dahlgren MK, Racine M, Lukas SE. Age of onset of marijuana use and executive function. Psychol Addict Behav. 2012;26(3):496–506.
Tait R, Mackinnon A, Christensen H. Cannabis use and cognitive function: 8-year trajectory in a young adult cohort. Addiction. 2011;106(12):2195–203.
Becker B, Wagner D, Gouzoulis-Mayfrank E, Spuentrup E, Daumann J. Altered parahippocampal functioning in cannabis users is related to the frequency of use. Psychopharmacology. 2010;209(4):361–74.
Solowij N, Stephens RS, Roffman RA, et al. Cognitive functioning of long-term heavy cannabis users seeking treatment. JAMA. 2002;287(9):1123–31.
Messinis L, Kyprianidou A, Malefaki S, Papathanasopoulos P. Neuropsychological deficits in long-term frequent cannabis users. Neurology. 2006;66(5):737–9.
Wadsworth EJ, Moss SC, Simpson SA, Smith AP. Cannabis use, cognitive performance and mood in a sample of workers. J Psychopharmacol. 2006;20(1):14–23.
Jager G, Van Hell HH, De Win MM, et al. Effects of frequent cannabis use on hippocampal activity during an associative memory task. Eur Neuropsychopharmacol. 2007;17(4):289–97.
Indlekofer F, Piechatzek M, Daamen M, et al. Reduced memory and attention performance in a population-based sample of young adults with a moderate lifetime use of cannabis, ecstasy and alcohol. J Psychopharmacol. 2009;23(5):495–509.
Bolla KI, Brown K, Eldreth D, Tate K, Cadet JL. Dose-related neurocognitive effects of marijuana use. Neurology. 2002;59(9):1337–43.
Hadjiefthyvoulou F, Fisk JE, Montgomery C, Bridges N. Prospective memory functioning among ecstasy/polydrug users: evidence from the Cambridge Prospective Memory Test (CAMPROMPT). Psychopharmacology. 2011;215(4):761–74.
Cristiani SA, Pukay-Martin ND, Bornstein RA. Marijuana use and cognitive function in HIV-infected people. J Neuropsychiatry Clin Neurosci. 2004;16(3):330–5.
Thames AD, Kuhn TP, Williamson TJ, Jones JD, Mahmood Z, Hammond A. Marijuana effects on changes in brain structure and cognitive function among HIV+ and HIV-adults. Drug Alcohol Depend. 2017;2017(170):120–7.
McLellan AT, Kushner H, Metzger D, et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat. 1992;9(3):199–213.
Gruber SA, Dahlgren MK, Sagar KA, Gönenç A, Lukas SE. Worth the wait: effects of age of onset of marijuana use on white matter and impulsivity. Psychopharmacology. 2014;231(8):1455–65.
APA. Diagnostic and statistical manual of mental disorders, Fourth Edition, text revision. Washington: American Psychiatric Association; 2000.
Wechsler D. Wechsler test of adult reading (WTAR) manual. San Antonio: Harcourt Assessment; 2001.
Sobell LC, Sobell MB. Timeline Follow-back user’s guide: a calendar method for assessing alcohol and drug use. Toronto: Addiction Research Foundation; 1996.
NIAAA. The physician’s guide to helping patients with alcohol problems. Washington, DC: National Institutes of Health; 1995.
McGahan PL, Griffith JA, Parente R, McLellan AT. Addiction severity index composite scores manual. Philadelphia: The University of Pennsylvania/Veterans Administration Center for Studies of Addiction; 1986.
First MB, Spitzer RL, Gibbon M, Williams JBW. Structured clinical interview for DSM-IV axis I disorders, research version, patient/non-patient edition. New York: Biometrics Research, New York State Psychiatric Institute; 1996.
Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59(Suppl 30):22–33.
Derogatis LR. Brief Symptom Inventory: administration, scoring, and procedures manual. 3rd ed. Minneapolis: National Computer Systems, Inc.; 1993.
Brandt J, Benedict RHB. Hopkins verbal learning test—revised professional manual. Lutz: Psychological Assessment Resources, Inc; 2001.
Benedict RHB. Brief visuospatial memory test-revised professional manual. Odessa: Psychological Assessment Resources, Inc.; 1997.
Lezac MD. Neuropsychological assessment. 3rd ed. New York: Oxford University Press; 1995.
Golden CJ. Stroop color and word test. Chicago: Stoelting; 1978.
Wechsler D. Wechsler Adult Intelligence Scale-Third Edition: Administration and Scoring Manual. San Antonio: Harcourt Brace; 1997.
Heaton RK, Grant I, Matthews CG. Comprehensive norms for an expanded Halstead-Reitan battery: demographic corrections, research findings, and clinical applications. Odessa: Psychological Assessment Resources; 1991.
Benton A, Hamsher K, Sivan A. Multilingual aphasia examination. 3rd ed. Iowa City: AJA Associates; 1983.
Gronwall DM. Paced auditory serial-addition task: a measure of recovery from concussion. Percept Mot Skills. 1977;44(2):367–73.
Stern RA, White T. Neuropsychological assessment battery: administration, scoring, and interpretation manual. Lutz: Psychological Assessment Resources, Inc; 2003.
Diehr MC, Cherner M, Wolfson TJ, Miller SW, Grant I, Heaton RK. The 50 and 100-item short forms of the Paced Auditory Serial Addition Task (PASAT): demographically corrected norms and comparisons with the full PASAT in normal and clinical samples. J Clin Exp Neuropsychol. 2003;25(4):571–85.
Heaton RK, Miller SW, Taylor MJ, Grant I. Revised comprehensive norms for an expanded Halstead-Reitan battery: demographically adjusted neuropsychological norms for African American and Caucasian adults. Lutz: Psychological Assessment Resources, Inc; 2004.
Norman MA, Moore DJ, Taylor M, et al. Demographically corrected norms for African Americans and Caucasians on the hopkins verbal learning test-revised, brief visuospatial memory test-revised, stroop color and word test, and wisconsin card sorting test 64-card version. J Clin Exp Neuropsychol. 2011;33(7):793–804.
Stern RA, White T. NAB digits forward/digits backward test: professional manual. Lutz: Psychological Assessment Resources, Inc. (PAR); 2009.
Heaton RK, Grant I, Butters N, et al. The HNRC 500–neuropsychology of HIV infection at different disease stages. HIV Neurobehavioral Research Center. J Int Neuropsychol Soc. 1995;1(3):231–51.
Carey CL, Woods SP, Gonzalez R, et al. Predictive validity of global deficit scores in detecting neuropsychological impairment in HIV infection. J Clin Exp Neuropsychol. 2004;26(3):307–19.
Jacobus J, Tapert SF. Effects of cannabis on the adolescent brain. Curr Pharmaceut Des. 2014;20(13):2186–93.
Tseng A, Seet J, Phillips EJ. The evolution of three decades of antiretroviral therapy: challenges, triumphs and the promise of the future. Br J Clin Pharmacol. 2015;79(2):182–94.
Deeks SG, Lewin SR, Havlir DV. The end of AIDS: HIV infection as a chronic disease. Lancet. 2013;382(9903):1525–33.
Hoffmann DE, Weber E. Medical marijuana and the law. New Engl J Med. 2010;362(16):1453–7.
Zogg JB, Woods SP, Weber E, et al. HIV-associated prospective memory impairment in the laboratory predicts failures on a semi-naturalistic measure of health care compliance. Clin Neuropsychol. 2010;24(6):945–62.
Hinkin CH, Castellon SA, Durvasula RS, et al. Medication adherence among HIV+ adults: effects of cognitive dysfunction and regimen complexity. Neurology. 2002;59(12):1944–50.
Hinkin CH, Hardy DJ, Mason KI, et al. Medication adherence in HIV-infected adults: effect of patient age, cognitive status, and substance abuse. AIDS. 2004;18(Supp 1):19–25.
Contardo C, Black AC, Beauvais J, Dieckhaus K, Rosen MI. Relationship of prospective memory to neuropsychological function and antiretroviral adherence. Arch Clin Neuropsychol. 2009;24(6):547–54.
Ettenhofer ML, Foley J, Castellon SA, Hinkin CH. Reciprocal prediction of medication adherence and neurocognition in HIV/AIDS. Neurology. 2010;74(15):1217–22.
Andrade A, McGruder H, Wu A, et al. A programmable prompting device improves adherence to highly active antiretroviral therapy in HIV-Infected subjects with memory impairment. Clin Infect Dis. 2005;41(6):875–82.
Harrigan PR, Hogg RS, Dong WWY, et al. Predictors of HIV drug-resistance mutations in a large antiretroviral-naive cohort initiating triple antiretroviral therapy. J Infect Dis. 2005;191(3):339–47.
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. NEJM. 2011;365(6):493–505.
van Gorp WG, Rabkin JG, Ferrando SJ, et al. Neuropsychiatric predictors of return to work in HIV/AIDS. J Int Neuropsychol Soc. 2007;13(1):80–9.
de Wit H. Impulsivity as a determinant and consequence of drug use: a review of underlying processes. Addict Biol. 2009;14(1):22–31.
Verdejo-Garcia A, Lawrence AJ, Clark L. Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci Biobehav Rev. 2008;32(4):777–810.
Squeglia LM, Cservenka A. Adolescence and drug use vulnerability: findings from neuroimaging. Curr Opin Behav Sci. 2017;13:164–70.
Acknowledgements
This study was supported by grants from the National Institute on Drug Abuse (F31-DA035131, K23-DA028660, & R03-DA035670), the National Institute of Allergy and Infectious Diseases (T32-AI007392), & the Duke Center for AIDS Research (P30-AI064518).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.
Informed consent
Informed consent was obtained from all individual participants included in the study.
Rights and permissions
About this article
Cite this article
Skalski, L.M., Towe, S.L., Sikkema, K.J. et al. Memory Impairment in HIV-Infected Individuals with Early and Late Initiation of Regular Marijuana Use. AIDS Behav 22, 1596–1605 (2018). https://doi.org/10.1007/s10461-017-1898-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10461-017-1898-z